NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind.
| Revenue (Most Recent Fiscal Year) | $2.69M |
| Net Income (Most Recent Fiscal Year) | $-8.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.45 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 86.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -286.10% |
| Net Margin (Trailing 12 Months) | -293.36% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -297.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 11.61 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.19 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.22M |
| Free Float | 6.12M |
| Market Capitalization | $21.86M |
| Average Volume (Last 20 Days) | 4.79M |
| Beta (Past 60 Months) | 3.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |